论文部分内容阅读
目的介绍趋化因子及其受体,尤其是CCL19/CCL21-CCR7及CXCL12-CXCR4轴在胃癌发生、发展中的作用。方法查阅国内、外近年来有关趋化因子及其受体与胃癌关系的文献并作综述。结果趋化因子及其受体通过对胃癌生长微环境的调控,CCL19/CCL21-CCR7在胃癌淋巴结转移过程中起着突出作用,CXCL12-CXCR4轴在胃癌腹膜转移过程中起着关键作用。CCR7可能成为特异性评价胃癌淋巴结转移潜能的分子标志物。阻断CXCL12-CXCR4轴有助于推动进展期胃癌腹膜转移治疗策略的进一步发展。结论趋化因子及其受体从不同的方面促进胃癌的演进,了解这些方面的机理可以为未来的治疗提供理论依据。以趋化因子及其受体作为一种胃癌标志物和肿瘤治疗的新靶点,在胃癌侵袭转移的评估、预后判断和治疗方面将有着广阔的临床应用前景。
Objective To introduce the role of chemokines and their receptors, especially CCL19 / CCL21-CCR7 and CXCL12-CXCR4 axis in the occurrence and development of gastric cancer. Methods To review the literature about the relationship between chemokine and its receptor and gastric cancer at home and abroad in recent years. Results Chemokines and their receptors play a prominent role in the metastasis of gastric cancer by regulating the microenvironment of gastric cancer. The CXCL12-CXCR4 axis plays a key role in the peritoneal metastasis of gastric cancer. CCR7 may be a specific molecular marker for evaluating lymph node metastasis potential in gastric cancer. Blocking the CXCL12-CXCR4 axis contributes to the further development of strategies for the treatment of peritoneal metastases in advanced gastric cancer. Conclusions Chemokines and their receptors promote the development of gastric cancer in different aspects. Understanding these mechanisms can provide theoretical basis for future treatment. Chemokines and their receptors as a new target of gastric cancer markers and tumor therapy will have broad clinical application prospects in the assessment of gastric cancer invasion and metastasis, prognosis and treatment.